This 120% increase can be primarily attributed to IDEX stock since the end of 2017. 1. The company's P/S ratio increased 33% from 6.6x in 2017 to 8.7x trailing revenue, 2. Revenue of IDEXX Laboratories compared to $2.0 billion in 2017, an increase of 68% to $3.3 billion over the past twelve months, and 3. Its total outstanding shares declined 4%.